Flu activity increased in five regions: the Northeast, New England, the Middle Atlantic, the Midwest, and the Central states.
Just over 40% of mothers said their young babies had received Beyfortus, the new RSV antibody vaccine.
Influenza B proportions are rising in regions where flu activity is trending upward.
Preterm infants accounted for 25% of RSV-associated hospitalizations.
Nirsevimab effectiveness was greater than 70% in infants under 9 months.
Influenza B activity is fueling rises in the Midwest and Central regions.
The hospitalization ratio of human rhinovirus to RSV days was 51%.
The FDA expects to make a decision by early June.
Flu indicators are rising in some parts of the nation, especially the Midwest and South-Central regions.
Hospitalization rates were highest among children 0 to 2 months old.